Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants.

The new drug, developed by Novartis and MMV, isn't a malaria vaccine, but can help treat babies with the disease.

Malaria caused 597,000 deaths worldwide in 2023, with children under 5 accounting for 76 percent of all malaria deaths in the ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

The first malaria treatment for newborns and young infants has received approval from Swiss health regulators, with eight ...

The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, ...

Swiss medicines regulator Swissmedic has approved Coartem Baby, a Novartis anti-malaria drug developed for infants weighing ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...

In a historic move, Swissmedic has approved Coartem Baby, the first malaria treatment specifically for newborns and young ...